Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $755.000 thousand which missed the analyst consensus estimate of $2.470 million by 69.43 percent. This is a 73.80 percent decrease over sales of $2.882 million the same period last year.